Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.3852W HIGH $19.19
Volume
46.46 K
Value Traded
206.33 K
Short % Float
0.15%
Days to Cover
1.0
-6.18%Week
+3.45%1 Month
-91.3%3 Month
+7.45%6 Month
-99.75%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
29.76 M
EPS (TTM)
-0.10
P/E Ratio
-
Ent. Value
32.16 M
Total Shares
43.02 M
Float Shares
40.34 M
Insiders
6.23%
Institutions
0.47%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CPHI Catalyst Timeline
Dated clinical, regulatory and corporate events for China Pharma Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for China Pharma Holdings, Inc.
26Total events
0Upcoming
1Tier-1 (high impact)
2006 to 2026Coverage
Event history 26
▼Equity OfferingCorporate
Closing of $5.0 million registered direct offering of 2,500,000 shares at $2.00 per share
▼Equity OfferingCorporate
Pricing of $5 million registered direct offering of 2.5 million shares at $2 per share
◆Reverse Stock SplitCorporate
NYSE American deficiency letter requires reverse stock split or price improvement by March 6, 2018
▼Other Regulator MilestoneEx-US Regulatory
Decided not to renew National High-Tech Enterprise status in 2017, resulting in higher tax rate
●Other Regulator MilestoneEx-US Regulatory
PRC State Council issued Opinions on Consistency Evaluation of Generic Drugs in March 2016
▼Program DiscontinuationCorporate
Suspended development of pipeline products in 2016 due to consistency evaluation uncertainties
▼Other Regulator MilestoneEx-US Regulatory
Recognized impairment loss on five medical formulas in 2016 due to government policies
▲Other Regulator MilestoneEx-US Regulatory
Received new GMP certificates for tablet, capsule, and cephalosporin product lines at old factories in 2015
▲Other Regulator MilestoneEx-US Regulatory
Received new GMP certificates for dried powder and liquid injectable product lines at new facility in 2014
▲Other Regulator MilestoneEx-US Regulatory
Renewed National High-Tech Enterprise status in Q3 2013, providing preferential tax rate through 2016
▲Product LaunchPost-Market
Launch of two new products expected during first half of 2008
cold/flusource ↗
▼Equity OfferingCorporate
Private placement of 2.5M shares at $1.70/share and 2.5M warrants, net proceeds ~$3.85M
▲Quarterly UpdateCorporate
Announced preliminary 2007 revenue of ~$33M, >50% increase from 2006
▲Product LaunchPropylgallatePost-Market
Launch of Propylgallate
cardiovascular & cerebrovascular conditionssource ↗
▲Product LaunchOzagrelPost-Market
Launch of Ozagrel
cardiovascular & cerebrovascular conditionssource ↗
Past FDA Catalysts and PDUFA Decisions
How CPHI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every CPHI program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Li ZhilinDirector, Officer (CEO & Interim CFO), 10% Owner | Grant/Award | 1,760,000 13,810,000 held | $0.67 | 09/09/2021 |
Hedge Fund 13F Activity
Hedge Funds invested in CPHI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CPHI for Q2 2026. | ||||
CPHI Institutional Ownership Trends
CPHI Short Interest
Shares sold short, counted twice a month.
0.15%
Short % of Float
of tradable shares sold short
61.9K
Shares Sold Short
-66.1% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
344.0K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CPHI ranks across every disease it competes in
Competitive Position is a premium feature
See how CPHI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCPHI News
CPHI▼ -17.8%on this news· ran to -35% by day 3
China Pharma Holdings, Inc. Announces Closing of $5.0 Million Registered Direct Offering
China Pharma Holdings, Inc. has successfully closed a registered direct offering, raising $5 million by selling 2.5 million shares at $2.00 each. The funds will be utilized for working capital and general corporate purposes. The offering was facilitated by FT Global Capital, Inc. and follows the company's effective shelf registration with the SEC.
Read more →CPHI▼ -78.9%on this newsshared move
China Pharma Announces Pricing of $5 Million Registered Direct Offering
China Pharma Holdings, Inc. has announced a registered direct offering of 2.5 million shares priced at $2 each, aiming to raise $5 million. The proceeds will be allocated for working capital and general corporate purposes. The offering is expected to close on July 23, 2026, with FT Global Capital acting as the exclusive placement agent.
Read more →CPHI▼ -78.9%on this newsshared move
China Pharma Holdings, Inc. Comments on Unusual Market Activity
China Pharma Holdings, Inc. addressed unusual market activity on July 21, 2026, stating that it was not aware of any material corporate developments to explain the fluctuations. The NYSE American contacted the company as part of its standard procedure. The company cautioned investors to rely on official filings and press releases for accurate information.
Read more →CPHI▼ -26.4%on this news· ran to -39% by day 3
China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity
China Pharma Holdings, Inc. announced it is unaware of any undisclosed information that could explain the unusual market activity in its stock observed on July 10, 13, and 15, 2026. The NYSE American contacted the company regarding this activity. The company maintains a diversified portfolio focused on high-incidence diseases in China.
Read more →CPHI▼ -7%on this news· ran to -46% by day 1
China Pharma Holdings Inc. Announces 1-for-10
China Pharma Holdings Inc. has announced a 1-for-10 reverse stock split set to take effect on April 15, 2025. This decision was unanimously approved by the Company's Board and stockholders. Following the split, every 10 shares will convert into one share, without issuing fractional shares. This action is part of the Company's strategy to improve its stock price and overall market perception in a competitive landscape.
Read more →CPHI▼ -7%on this news· ran to -46% by day 1
China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split
China Pharma Holdings Inc. announced a 1-for-10 reverse stock split effective April 15, 2025. This decision was authorized by the Board of Directors and approved by stockholders. The split will convert every 10 shares into one, without issuing fractional shares. The company continues to focus on high-incidence diseases in China.
Read more →CPHI▼ -9.8%on this news
China Pharma Holdings, Inc. Completes Full Redemptions Under Convertible Note Agreement with Streeterville
China Pharma Holdings, Inc. has successfully completed all redemptions under its Convertible Promissory Note agreement with Streeterville Capital, LLC. This achievement enhances the company's financial stability and demonstrates its commitment to fiscal management. With the redemptions finalized, China Pharma aims to pursue growth and develop innovative pharmaceutical solutions for critical healthcare needs in China.
Read more →CPHIChina Pharma Announces the Entry of "At-The-Market" Equity Offering
China Pharma Holdings, Inc. has announced an at-the-market equity offering that allows the company to raise up to $600,000 by selling shares of common stock. A prospectus supplement has been filed with the U.S. Securities and Exchange Commission outlining the terms of the sale, including pricing conditions. The company’s investor may choose to purchase shares at their discretion between December 12, 2024, and December 31, 2024. However, there are no guarantees regarding the actual issuance or sale of any shares.
Read more →CPHIChina Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025
China Pharma Holdings, Inc. plans to launch its Dry Eye Disease Therapeutic Device in Q1 2025. The device aims to improve treatment for dry eye disease, which affects a significant portion of the Chinese population. The company has completed production and testing, positioning itself in a growing market projected to reach $579.51 million by 2030.
Read more →CPHIChina Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split Haikou City, China
China Pharma Holdings Inc. is implementing a 1-for-5 reverse stock split effective March 6, 2024, with trading set to begin on a split-adjusted basis on the NYSE American. The decision, approved by the Board of Directors and stockholders, aims to consolidate shares to improve market value. This split does not alter stockholders' percentage interests except for adjustments from fractional shares. The company continues to focus on developing products for major health issues in China.
Read more →CPHIChina Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split
China Pharma Holdings Inc. announced a 1-for-5 reverse stock split effective March 6, 2024. This decision was approved by the Board of Directors and stockholders in late 2023. The split aims to consolidate shares, potentially improving market perception and attracting institutional investors. The company continues to focus on critical health conditions in China.
Read more →CPHI▲ +30.2%on this news
China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device
China Pharma Holdings, Inc. has announced that its Dry Eye Disease therapeutic device has successfully passed third-party testing. The company is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China, with expectations to launch in the first half of next year. The device aims to address a significant market gap in treating Dry Eye Disease, which affects millions globally.
Read more →CPHIChina Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs
China Pharma Holdings, Inc. announced that its subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., received approval for its candesartan tablets from the National Medical Products Administration of China. This approval indicates that the tablets meet the quality and efficacy standards required for generic drugs, allowing them to replace innovator drugs in clinical settings. The product is significant for managing hypertension and reducing risks associated with cardiovascular diseases.
Read more →CPHIChina Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split Haikou City, China
China Pharma Holdings Inc. announced a 1-for-10 reverse stock split that will take effect on March 6, 2023, allowing trading to begin on a split-adjusted basis. The decision was approved unanimously by the Board of Directors and is expected to affect all shareholders uniformly. No fractional shares will be issued as a result of the split, and the new CUSIP number for the stock has been provided. The company continues to focus on developing a diversified portfolio of pharmaceutical products in China.
Read more →CPHIChina Pharma Announces Receipt of Noncompliance Notice from NYSE American
Pharma Announces Receipt of Noncompliance Notice from NYSE American CITY, December 2, 2022 - China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that on December 1, 2022, received a notif
Read more →CPHI▼ -7%on this news
China Pharma Announces Receipt of Notification of NYSE American Listing Deficiency Haikou City, China
China Pharma Announces Receipt of Notification of NYSE American Listing Deficiency Haikou City, China - September 30, 2022 - China Pharma Holdings, Inc. (NYSE American: CPHI; the "Company") today announced that on September 26, 2022, the Company received notification (the "De
Read more →CPHIChina Holdings Announces Notification of NYSE American
China Pharma Holdings, Inc. Phone: +86-898-6681-1730 (China) Email: hps@chinapharmaholdings.com China Pharma Holdings, Inc. Announces Notification of NYSE American Haikou City, China - September 12, 2017 - China Pharma Holdings, Inc. (NYSE American: CPHI; the "Company") tod
Read more →About China Pharma Holdings, Inc.
Headquarters2ND FLOOR, NO. 17, JINPAN ROAD, HAINAN PROVINCE, F4, 570216
BIOPHARMAWATCH ELITE PLUS
Trade the next CPHI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime